ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome (NCT02848274)
Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients With Advanced Mycosis Fungoides and Sézary Syndrome
🩺 Plain-English Summary (8th-Grade Level)
The purpose of the study is to develop a prognostic index model for the rare disease of mycosis fungoides and sezary syndrome. This will be done by collecting standardized clinical data at various institutions. The investigators hope this will enable the identification of low- and high-risk groups for survival in order to improve patient care and outcome.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (2 items) and avoid the listed exclusions (4 items).
Location: City of Hope — Duarte, California
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria
- Patients diagnosed with early stage MF/SS (Stages IA-IIA) before progressing to advanced stage
- Patients diagnosed with advanced MF/SS more than 6 months prior to initial presentation to the participating center
- Exclude one-time consultation type of new patients.
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (13 Sites)
- City of Hope — Duarte, California
- Stanford University, School of Medicine — Palo Alto, California
- University of Iowa — Iowa City, Iowa
- Hackensack University Medical Center — Hackensack, New Jersey
- University of Pittsburg — Pittsburgh, Pennsylvania
- University of Texas Southwestern — Dallas, Texas
- University of Utah Hospital — Salt Lake City, Utah
- Hospital Italiano de Buenos Aires — Buenos Aires,
- Peter MacCallum Cancer Center, — Melbourne,
- University of Sao Paulo Medical School — São Paulo,
- Peking University First Hospital — Beijing,
- The University of Tokyo — Tokyo,
- University Hospitals Birmingham — Birmingham,
📞 Contact the Study Coordinator
Phone: (650) 709-7838
Email: tatianan@stanford.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Mycosis Fungoides
- Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome — Basking Ridge, New Jersey
- Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides — Chicago, Illinois
- A Study of VG712 in Patients With Mycosis Fungoides — Tampa, Florida
- Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients — Stanford, California
- Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides — Houston, Texas
Explore by condition: All Mycosis Fungoides clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.